2026年全球肝炎报告——信息表

Global hepatitis report 2026 Situation and response Viral hepatitis is one of the world’s most important public health challenges. HepatitisB virus (HBV) and hepatitis C virus (HCV) continue to cause chronic infection, leading to Although both infections are preventable and treatable, HBV and HCV togetheraccount for more than 95% of mortality from viralhepatitis. In highly endemic areas, most chronic HBV infections occur in children aged under 5 years, either through mother-to-child transmission at birth or horizontal transmission in childhood through person-to-person contact in the presence ofopen cuts and sores. People can also be infected with HBV through exposure to infected blood via needle-stick injuries, The global burden of viral hepatitis Incidence Mortality In 2024, there were1.8million new HBV and HCVinfections, including: In 2024, viral hepatitis B and C caused1.3milliondeaths worldwide, mostly from liver cirrhosis and Between 2015 and 2024,reductions innew infections were as follows: Ten countries accounted for69% of chronicHBV deathsand ten countries accountedfor58% of HCV deaths, showing major Eliminating viral hepatitis 85 countries have surpassed the2030targetof reducing chronic HBVprevalence in children aged under five Global progress towards eliminatingviral hepatitis as a public health threatby 2030 is off track, but still achievable Priorities for global and regional action To achieve the 2030 global viral hepatitis elimination targets, there arefive major priorities for global and regional action: Despite the availability of effective diagnostics and medicines, access tocare remains critically limited in many high-burden settings. scaling uptreatment for people with chronic HBV infection,especially in the WHO African and Western Pacific regions;scaling uptreatment for people with HCV infection, especially inthe WHO Eastern Mediterranean Region;improving thecoverage of hepatitis B birth‑dose vaccination, Under current trajectories, the global target of a65% reduction inhepatitis‑related deaths by 2030, compared with 2015, will not beachievedwithout rapid scale-up of testing and treatment. The 2030 target of a 95% reduction in new hepatitis B infections requiresa massive improvement in the coverage of hepatitis B birth‑dosevaccination in the African regionand improved coverage of antiviral With sustained political commitment, adequate investment andequitable access to proven interventions, elimination of viralhepatitis as a public health threat by 2030 remains achievable.